A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Durvalumab (Primary) ; Guadecitabine (Primary)
- Indications Bile duct diseases; Cholangiocarcinoma; Gallbladder cancer; Liver cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Oct 2017 Planned End Date changed from 25 Sep 2020 to 30 Oct 2020.
- 02 Oct 2017 Planned primary completion date changed from 25 Sep 2019 to 30 Oct 2019.
- 02 Oct 2017 Planned initiation date changed from 25 Sep 2017 to 30 Oct 2017.